Next-generation functional drug discovery platform
Curve has developed a drug discovery platform to address the most challenging and complex disease targets. The company’s innovative technology allows high-throughput functional screening of a proprietary DNA-encoded (Microcycle®) library inside mammalian cells.
Curve is using this platform to develop a pipeline of first-in-class small-molecule therapeutics against challenging cancer targets, including intracellular protein-protein interactions and pioneer factors.
CEO Simon Kerry
Advent Contact Simon Kerry I Shahzad Malik
Private Companies
Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
Press Release. Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and…
Read More
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Press Release. Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables direct discovery…
Read More
